This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
PAREXEL's Acquisition by Pamplona Approved by Shareholders
by Zacks Equity Research
The long-awaited PAREXEL (PRXL) acquisition by Pamplona Capital Management finally receives shareholders' approval. Moreover, the company plans to go private post-acquisition.
Ride Out MedTech Volatility With These 3 Ultra-Safe Stocks
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these three low-beta MedTech stocks stand out as the most suitable value picks.
PAREXEL Ties Up With Osaka International Cancer Institute
by Zacks Equity Research
We believe tie-ups like these will help PAREXEL (PRXL) drive its top and bottom line. The company also has a competitive edge in the Asia-Pacific markets.
Healthcare Q2 Earnings Due on Aug 2: HUM, PRXL, MOH, TDOC
by Zacks Equity Research
The Medical sector is likely to benefit from inorganic growth, product launches, technology upgrades. However, regulatory hassles might offset its growth potential.
PAREXEL (PRXL) Gets CEO Cancer Gold Standard Accreditation
by Zacks Equity Research
PAREXEL International Corporation (PRXL) was recently nominated as a CEO Cancer Gold Standard employer by CEO Roundtable on Cancer.
Company News for June 21, 2017
by Zacks Equity Research
Companies in the News are: TSLA,LEN,PRXL,NK
PAREXEL Announces Acquisition by Pamplona Capital for $5B
by Zacks Equity Research
PAREXEL International Corporation (PRXL) recently announced that it has agreed to be acquired by Pamplona Capital Management, LLP.
PAREXEL to Launch Connected Journey Data-Driven Services
by Zacks Equity Research
PAREXEL International Corporation (PRXL) recently announced the launch of its proprietary data-driven services, Connected Journey.
PAREXEL (PRXL) Launches Sensor for Clinical Trial Market
by Zacks Equity Research
PAREXEL International Corporation (PRXL), a global biopharmaceutical services company and provider of clinical research and logistics, recently announced the launch of its patient sensor solution.
Falling Earnings Estimates Signal Weakness Ahead for PAREXEL (PRXL)
by Zacks Equity Research
PAREXEL (PRXL) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
PAREXEL (PRXL): Moving Average Crossover Alert
by Zacks Equity Research
Are you a technical investor? If so, it may be time to consider PAREXEL International Corporation (PRXL) for your portfolio.